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Comorbidity landscape of the Danish patient population
affected by chromosome abnormalities
Isabella Friis Jørgensen, MSc 1, Francesco Russo, PhD 1, Anders Boeck Jensen, PhD2,
David Westergaard, PhD1, Mette Lademann, PhD 1, Jessica Xin Hu, PhD1, Søren Brunak, PhD1 and
Kirstine Belling, PhD 1
Purpose: Most chromosome abnormality patients require long-
term clinical care. Awareness of mosaicism and comorbidities can
potentially guide such health care. Here we present a population-
wide analysis of direct and inverse comorbidities affecting patients
with chromosome abnormalities.
Methods:We extracted direct and inverse comorbidities for the 11
most prevalent chromosome abnormalities from the Danish
National Patient Registry (covering 6.9 million patients hospitalized
between 1994 and 2015): trisomy 13, 18, and 21, Klinefelter (47,
XXY), triple X, XYY, Turner (45,X), Wolf–Hirschhorn, Cri-du-
chat, Angelman, and Fragile X syndromes (FXS). We also
performed four sub-analyses for male/female Down syndrome
(DS) and FXS and non-mosaic/mosaic DS and Turner syndrome.
Results: Our data cover 9,003 patients diagnosed with at least one
chromosome abnormality. Each abnormality showed a unique
comorbidity signature, but clustering of their profiles underlined
common risk profiles for chromosome abnormalities with similar
genetic backgrounds. We found that DS had a decreased risk for
three inverse cancer comorbidities (lung, breast, and skin) and that
male FXS and non-mosaic patients have a much more severe
phenotype than female FXS and mosaic patients, respectively.
Conclusion: Our study underlines the importance of considering
mosaicism, sex, and the associated comorbidity profiles of
chromosome abnormalities to guide long-term health care of
affected patients.
Genetics inMedicine (2019) 21:2485–2495; https://doi.org/10.1038/s41436-
019-0519-9
Keywords: comorbidity; inverse comorbidity; chromosome
abnormality; Down syndrome; mosaicism
INTRODUCTION
Chromosome abnormalities result from either gain or loss of
entire chromosomes (aneuploidy), or parts of chromosomes
(structural abnormalities).1 In general, chromosome abnorm-
alities have major, but varying, impacts. Mosaicism also exists
with varying frequency.2 Mosaic patients may show very few
clinical symptoms, yet, the impact of a mosaicism depends on
the number and cell types affected.3–5 For aneuploidies, sex
chromosome aneuploidies are more compatible with life than
autosomal aneuploidies, where only three trisomies are
tolerated: Patau (trisomy 13), Edwards (trisomy 18), and
Down syndromes (DS) (trisomy 21). However, infants born
with trisomy 13 or 18 typically die within the first weeks.6
Prevalent sex chromosome aneuploidies are Klinefelter
syndrome (KS) (47,XXY), triple X syndrome (47,XXX),
XYY syndrome (47,XYY), and Turner syndrome (TS) (45,X).
Structural abnormalities can be caused by partial chromo-
some deletions such as in Wolf–Hirschhorn and Cri-du-chat
syndromes caused by partial deletions of the short arm of
chromosome 4 and 5, respectively,7 or other chromosome
alterations such as in Angelman syndrome (deletions or
variants in UBE3A on chromosome 158) and Fragile X
syndrome (FXS) (expansion of FMR1 on chromosome X).9
FXS is associated with cognitive deficits and behavioral
problems, yet, females are most often compensated by the
normal X chromosome and their phenotypes vary
substantially.10
The birth rate of chromosome abnormalities is estimated to
17–31/10,000 in the European population. Many of them will
need lifelong clinical care,11 which can be guided by
knowledge of common comorbidities, defined as diseases
that co-occur more frequently with a primary disease
compared with controls. Previous studies have described
disease course and clinical characteristics of chromosome
abnormalities (reviewed by Tyler et al.12) including specific
comorbidities. DS, KS, and TS are especially well described
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because numerous individuals are affected and their life
expectancy is relatively high. DS is typically diagnosed at
birth, TS usually shows during puberty, while KS is most often
identified in adulthood when evaluating infertility. DS is the
most common chromosome disorder causing intellectual
disability. DS patients are often affected by comorbidities such
as gastrointestinal malformations, congenital heart defects,
respiratory disease, and autoimmune diseases.13 KS patients
have a widely varying phenotype, but common characteristics
are small testes, narrow shoulders, broad hips, sparse body
hair, gynecomastia, and decreased verbal intelligence.14 It is
estimated that KS causes 1–3% of all male infertility
cases.4,15,16 Additionally, KS patients are often affected by
several other comorbidities, such as osteoporosis, diabetes
mellitus, cardiac diseases, and cognitive disorders.4 TS is the
only common monosomy. The majority of TS women are
infertile due to early ovarian failure, usually before puberty.17
Known comorbidities of TS includes cardiovascular, neuro-
logical, genitourinary, and skeletal defects.18
The life expectancy of aneuploidy patients is affected by
their comorbidity burden. Although DS patients have a lower
life expectancy than the general population, institutionaliza-
tion and advantages in medical care have increased their life
expectancy almost fourfold in the past 40 years.19 KS patients
have an increased mortality mainly due to infectious,
neurological, circulatory, pulmonary, and urinary tract
diseases,20 while TS is associated with a threefold increase
in overall mortality and a life expectancy reduced by up to 13
years.21
There is an increasing interest in studying disease–disease
relationships, direct but also inverse comorbidities, defined as
diseases that co-occur less frequently with a primary disease
compared with controls. Knowledge of disease dependencies
can provide knowledge of disease-causing or disease-
protective genes and multifunctional proteins, and potentially
guide disease prevention or treatment development.22 Central
nervous system disorders have previously been associated
with decreased risk of cancer.23 DS in particular has shown
decreased risk of solid tumors, e.g. embryonal tumors, breast
and skin cancer. In contrast, DS patients have increased risk
of other cancers such as acute leukemia and testicular
cancer.24 To the best of our knowledge no inverse
comorbidities have been identified for the remaining ten
chromosome abnormalities included in this study.
Previous studies of chromosome abnormality comorbidities
have mainly focused on one patient group at a time, on direct
comorbidities only, and were often based on only a few
patients.25 Thus, any shared consequences of having an
altered karyotype have yet not been studied in a data-driven
manner. Here, we present a population-wide, systematic, and
comparative analysis of direct and inverse comorbidities in
patients with the 11 most common chromosome abnormal-
ities in the Danish population. The results of this study can
potentially guide clinicians in the long-term health care of
affected patients and possibly increase our knowledge of
disease genes and mechanisms.
MATERIALS AND METHODS
Data
Diagnoses from the Danish National Patient Registry
(DNPR)26 covering 6.9 million patients and more than 108
million hospital encounters between 1994 and 2015 were
available. The diagnoses were encoded in the International
Classification of Diseases version 10 (ICD-10), which
hierarchically orders diseases in 21 chapters that are
subdivided into 227 blocks of similar diseases and 1,702
disease-specific level 3 codes. The level 3 codes are further
subdivided with up to four additional characters to indicate
etiology, anatomic site, severity, etc. Chromosome abnorm-
alities are encoded in ICD-10 chapter XVII “Congenital
malformations, deformations and chromosomal abnormal-
ities” in the block Q90–Q99 “Chromosomal abnormalities,
not elsewhere classified.” Eleven well-defined chromosome
abnormalities from this block with at least 50 patients each
were identified: Patau syndrome (trisomy 13), Edwards
syndrome (trisomy 18), DS (trisomy 21), KS (47,XXY), triple
X syndrome, XYY syndrome, TS (45,X), Wolf–Hirschhorn
syndrome, Cri-du-chat syndrome, Angelman syndrome, and
FXS. Four sub-analyses where also performed: female/male
DS and FXS, and non-mosaic/mosaic DS and TS patients
where each subgroup had at least 50 patients. Only patients
with either a mosaic or a nonmosaic diagnosis in the registry
were included in the subgroup analysis. See Table 1 for
specific ICD-10 codes for each patient group.
Extraction of direct and inverse comorbidities
Direct and inverse comorbidities were identified as the over-
or under-occurrence of a disease in chromosome abnorm-
ality patients compared with sex and year of a birth-
matched control group. A control population was randomly
drawn for each patient group from a pool of patients not
having any diagnoses in block Q90–Q99 “Chromosomal
abnormalities, not elsewhere classified.” Every patient was
matched to 20 controls to have enough controls to pick up
rare diseases, but still not give the test arbitrarily strong
statistical power.25
Association strength was assessed using the relative risk
(RR) measure. A pseudo count of 1 was added to the
calculation to avoid RR overestimation of disease associa-
tions for rare diseases.25 Thus, let At be the number of
chromosome abnormality patients and AX the number of
these patients also diagnosed with disease X. Likewise, let Ct
be the number of control patients and CX the number of
control patients also diagnosed with disease X. Then RR is
defined as:
Relative Risk RRð Þ ¼ AX þ 1ð Þ= At þ 1ð Þ
CX þ 1ð Þ= Ct þ 1ð Þ
A two-sided Fisher’s exact test was applied to calculate
p values, which were corrected for multiple testing using the
Benjamini–Hochberg procedure. For each direct and inverse
comorbidity, we required a minimum of five patients
diagnosed with disease X, a RR ≥ 1.5 or RR ≤ 0.5, and false
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discovery rate (FDR) ≤0.05.25 Hierarchical clustering with
Euclidean distance, using R3.3.1 and the ComplexHeatmap
package, of the RRs for all direct and inverse comorbidity
profiles was used to find common patterns.
The larger a population is, the more disease co-occurrences
are tested, and thus more comorbidities are potentially
identified. To account for the large difference in patient
number between non-mosaic and mosaic DS and TS
patients (Table 1), we randomly split the non-mosaic patients
into groups of a similar size to the mosaic patient group and
following identified direct and inverse comorbidities for the
two groups now of similar size.
Survival analysis
A Cox proportional hazards regression model was applied to
compare mortality of DS patients with 20 sex- and year of
birth–matched controls. A multivariate Cox analysis was used
to model survival time as a function of sex and group using
survival and survminer in R3.3.1. Survival difference between
DS patients and controls was visualized using Kaplan–Meier
curves. The proportional hazards assumption in the Cox
regression model was tested using scaled Schoenfeld residuals.
Additionally, a two-sided chi-square test was used to assess
the difference in incidence rate of three malignant solid
cancers between DS patients and sex- and age-matched
controls.
Change in comorbidity burden and life expectancy
Disease distributions across the ICD-10 chapters were
calculated for DS, KS, and TS. The percentage of the patient
group affected with diseases was summarized for each chapter
and visualized according to the age at first diagnosis. The
relative change in occurrence of comorbidities over time was
calculated for the DS, KS, and TS comorbidities for which at
least 10% of the patients had the diagnosis. The prevalence of
each comorbidity was calculated for each year in the registry
and adjusted for the number of DS, KS, or TS patients in the
specific year, respectively. Because the prevalence does not
take the potential age change of each patient group into
account it should be considered relative. A loess (locally
weighted smoothing) regression was used to fit a smooth
curve to discover changes in comorbidity prevalence
over time.
Life expectancy was calculated as the median age of death
for each patient group each year. Linear regression was
fitted to model the overall change in life expectancy.
Additionally, the number of births of DS, KS, and TS
patients and the median age of the patients in the registry
were calculated year-wise. The loess regression and linear
regression were done using the R packages ggplot2 and stats
(R version 3.3.1).
Data and materials approval
This study was approved by the Danish Data Protection
Agency, Copenhagen (ref: SUND-2016-83) and Statens
Serum Institut (ref: FSEID-00003092).
RESULTS
Direct and inverse comorbidities of chromosome
abnormality patients
In total, 9,003 patients in DNPR were diagnosed with at least
one chromosome abnormality in the period 1994–2015.
Direct (50% increased risk, RR ≥ 1.5) and inverse (50%
decreased risk, RR ≤ 0.5) comorbidities were systematically
identified for the 11 most prevalent chromosome abnormal-
ities by comparison of disease frequency in a sex- and year of
birth–matched background population. In total, 338 unique
direct and 60 unique inverse comorbidities were identified for
the 11 chromosome abnormalities. Direct comorbidities were
identified for all 11 chromosome abnormalities. Yet, sig-
nificant inverse comorbidities were only identified for DS, KS,
and TS. Tables S1 and S2 contain RR, FDR, and median age at
first diagnosis for all analyses.
Direct and inverse comorbidities were also identified for the
four subgroups: female/male DS and FXS, separately, and
non-mosaic/mosaic DS and TS, separately. Both significant
direct and inverse comorbidities were identified for male and
female DS (Tables S3 and S4). Only direct comorbidities were
identified for male and female FXS, and only three
comorbidities for female FSX (Table S5). Only patients with
specified karyotype were included in the comorbidity analyses
for non-mosaic and mosaic patients. In the comorbidity
analyses for the general patient population also patients with
an unspecified karyotype were included. Direct and inverse
comorbidities were identified for non-mosaic DS patients,
whereas only direct comorbidities were identified for mosaic
DS patients (Table S6). Only direct comorbidities were
identified for non-mosaic and mosaic TS patients, and only
one direct comorbidity was identified for mosaic TS patients
(Table S7). As for the comorbidity analyses of the full patient
populations we also included median age at first diagnosis for
all the subgroup analyses, which can be of interest for
comparison between female/male and non-mosaic and
mosaic patients. The specific ICD-10 codes for all patient
groups and the median age of chromosome abnormality
diagnosis are stated in Table 1. All supplementary tables with
inverse and direct comorbidities are available for download
(Tables S1–S7) or in an online, searchable form here: http://
chrom-abn.cpr.ku.dk/.
All chromosome abnormalities had a unique comorbidity
signature and none of the direct or inverse comorbidities were
shared between all 11 patient groups. Yet, most chromosome
abnormality patients had high RR of diseases from chapter
XVII “Congenital malformations, deformations and chromo-
somal abnormalities” and chapter V “Mental and behavioral
disorders.” Aneuploidies only had one direct comorbidity in
common, “Congenital malformations of cardiac septa” (Q21),
whereas the four smaller structural abnormalities had ten
shared direct comorbidities. Inverse comorbidities were
calculated for all 11 chromosome abnormalities, but were
only identified for DS (n= 56), KS (n= 1), and TS (n= 9).
Clustering the 14 RR profiles left the aneuploidies in one
group and smaller structural abnormalities in another (Fig. 1),
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which confirms common risk profiles for chromosome
abnormalities with similar genetic backgrounds.
Most chromosome abnormality patients were diagnosed
with DS, KS, or TS and, as expected, most comorbidities were
identified for these. In total, 17 direct comorbidities were
shared between DS, KS, and TS, and numerous comorbidities
were shared pairwise between the three (Fig. 2a). No inverse
comorbidity was shared between DS, KS, and TS, only six
inverse comorbidities overlapped between DS and TS
(Fig. 2b). In total, 56 inverse comorbidities were identified
for DS, only “Chronic disease of tonsils and adenoids” (J35)
(RR= 0.46) was observed as inverse comorbidity for KS, and
nine inverse comorbidities were identified for TS (Table 1 and
Table S2). Please see Text S1 for an elaborate presentation on
the shared direct and inverse comorbidities of DS, KS, and TS.
Cancer risk for Down syndrome patients
We discovered six direct comorbidities of DS from chapter
II “Neoplasms” (including one benign neoplasm): “Other
leukemias of specified cell type” (C94) (RR= 24.41),
“Leukemia of unspecified cell type” (C95) (RR= 12.07),
“Myeloid leukemia” (C92) (RR= 7.63), “Lymphoid leuke-
mia” (C91) (RR= 4.46), “Malignant neoplasm of testis”
(C62) (RR= 2.77), and “Benign neoplasm of mouth and
pharynx” (D10) (RR= 2.09). Contrarily, we observed six
inverse comorbidities related to cancer including three
benign and three malignant cancer types: “Malignant
neoplasm of bronchus and lung” (C34) (RR= 0.25),
“Malignant neoplasm of breast” (C50) (RR= 0.26), and
“Other malignant neoplasms of skin” (C44) (RR= 0.25)
(see Table S2), which supports earlier hypotheses.24 These
findings could be due to the shorter life expectancy of DS
patients confirmed by a multivariate Cox model (Table S8).
Our data showed that more than 80% of DS patients were
alive at age 50, whereas very few survived until age 75
(Fig. S1). To take this shorter life expectancy into account, all
DS patients were matched to 20 random controls with the
same age and sex where the incidence rate of the three
malignant cancers were compared with a chi-squared test
(Table S9). Still, all three cancers appeared significantly less in
DS patients, supporting the hypothesis of a solid cancer
protection phenotype of DS.
Variance in diagnosis age between aneuploidies
To better understand the unique comorbidity signatures of
the three most prevalent aneuploidies, we studied the age at
comorbidity diagnosis for each of the three patient groups
(Fig. 3a). DS, KS, and TS had comorbidities from many of the
same ICD-10 chapters, but the age at diagnosis differed: DS
was typically diagnosed at birth, which was seen from the
peak in chapter XVII “Congenital malformations, deforma-
tions and chromosomal abnormalities” (orange) in very early
life. The age at KS diagnosis varied but peaked around the age
of 30 with several diseases from chapter XIV “Diseases of the
genitourinary system” (yellow) including “Male infertility”
(N46). TS patients were usually diagnosed during childhood
and often had comorbidities from chapter VIII “Diseases of
the ear and mastoid process” (purple). Additionally, in early
adulthood several TS patients were diagnosed with chapter
XIV “Diseases of the genitourinary system” (yellow) including
“Female infertility” (N97).
Evolution of comorbidity burden and life expectancy
The comorbidity burden has changed over the past 20 years
for all three common aneuploidies. Figure 3b shows the
comorbidities affecting at least 10% of the DS, KS, and TS
patients, respectively. The incidence rate of “Congenital
malformations of cardiac septa” (Q21) has decreased for
DS. For KS, the relative incidence of “Male infertility” (N46),
“Testicular dysfunction” (E29), and “Hypertrophy of breast”
(N62) have increased, but then dropped again recently, while
the occurrence of “Asthma” (J45) has fluctuated during this
period. For TS patients the occurrence of hearing loss (H90
and H91) has increased, while the incidence of otitis media
(H65 and H66) has decreased. Still, the percentage of the
patient population affected by these comorbidities is relatively
low, especially for KS and TS.
The life expectancy of DS and TS has increased over the
past 20 years by 9 and 35 years, respectively, whereas the life
expectancy of KS has been stable (Fig. 3c). The median age of
the DS patients in the registry has slightly decreased, whereas
it has increased for KS and TS with 15 and 8 years,
respectively. The birth rate for DS has also dramatically
decreased during the past 20 years from around 70 patients a
year to around 35. The drop of DS births from 2004 to 2005
reflects new Danish guidelines offering prenatal screening
including a risk assessment for DS to all pregnant women.27
The birth rate has only slightly decreased for KS and TS
(Fig. S2).
Sex influences incidence of comorbidities
Enough DS and FXS patients (minimum 50 patients) in the
registry allowed us to perform analyses of direct and inverse
comorbidities for female and male patients separately. In
total, 181 and 194 direct comorbidities were found for female
Fig. 1 Comorbidity signatures for the 11 most prevalent chromosome abnormalities in the Danish population. The direct (n= 11) and inverse
(n= 3) comorbidity profiles are grouped vertically according to International Classification of Diseases version 10 (ICD-10) chapter (color scale explained at
the bottom) and hierarchically clustered horizontally based on their relative risk (RR) signatures (color scale right). To increase the quality of the clustering and
visualization, log2(RR +1) was used. Each chromosome abnormality had a specific signature, but they clustered in two distinct groups: aneuploidies (left)
and smaller structural abnormalities (right). The one direct comorbidity in common between all aneuploidies is written in italics to the left of the disease
chapter bar and the ten direct comorbidities in common between the four smaller structural abnormalities are listed as well. All direct and inverse
comorbidities are available in Tables S1 and S2, respectively.
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and male DS, respectively (Fig. 4a and Table S3). In fact,
female and male DS patients share more direct comorbidities
(n= 145) than they have specific ones (female n= 36 and
male n= 49) (Fig. S3a). Examples of female DS-specific direct
comorbidities were “Lymphoid leukemia” (C91), “Benign
neoplasm of mouth and pharynx” (D10), and “Edwards'
syndrome and Patau’s syndrome” (Q91), and examples of
male DS-specific direct comorbidities were “Asthma” (J45)
and “Cleft palate” (Q35). Further, 34 and 32 inverse
comorbidities were identified for female and male DS,
respectively, of which 19 were shared (Table S4). Female
DS-specific inverse comorbidities included “Depressive epi-
sode” (F32) and “Irritable bowel syndrome” (K58) and male
DS-specific inverse comorbidities included “Chronic ischemic
heart disease” (I25) and “Acute myocardial infarction” (I21).
The phenotypic impact of FXS varies between males and
females.10 Our analysis confirmed that FXS males suffer from
more comorbidities (n= 22) than FXS females (n= 3) (Fig. 4b
and Table S5). The only common direct comorbidity was
“Nonsuppurative otitis media” (H65) (Fig. S3b), whereas male
FXS-specific direct comorbidities included “Mental retarda-
tion” (F70, F71, F79) and “Epilepsy” (G40).
Non-mosaic patients have a more severe phenotype
compared with mosaic patients
For DS and TS, high enough patient counts and a clear ICD-
10 classification allowed us to perform comorbidity analyses
on non-mosaic/mosaic patients separately. A total of 211 and
15 direct comorbidities were identified for non-mosaic and
mosaic DS patients, respectively (Fig. 4c and Table S6). The
mosaic DS patients did not have any unique direct
comorbidities (Fig. S3c). Ten inverse comorbidities were
identified for non-mosaic DS patients including “Essential
(primary) hypertension” (I10) and “Angina pectoris” (I20).
No inverse comorbidities were identified for mosaic DS
patients.
A total of 48 and 1 direct comorbidities were identified for
non-mosaic and mosaic TS patients, respectively (Fig. 4d and
Table S7). The one direct comorbidity for mosaic TS patients,
“Other endocrine disorders” (E34) was shared between non-
147 48 45
17
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38
Down syndrome Turner syndrome
Klinefelter syndrome
a
50 6 3
0
0 0
1
Down syndrome Turner syndrome
Klinefelter syndrome
b
A46 Erysipelas
E10 Insulin-dependent diabetes mellitus
F70 Mild mental retardation
F79 Unspecified mental retardation
G40 Epilepsy
H25
I51
Senile cataract
Complications and ill-defined descriptions of
heart disease
J18 Pneumonia, organism unspecified
J96 Respiratory failure, not elsewhere classified
K02 Dental caries
K07 Dentofacial anomalies [including malocclusion]
M21 Other acquired deformities of limbs
M41 Scoliosis
Q21 Congenital malformations of cardiac septa
Q66 Congenital deformities of feet
Q74 Other congenital malformations of limb(s)
Q99 Other chromosome abnormalities, not elsewhere
classified
C50 Malignant neoplasm of breast
F10 Mental and behavioural disorders due to use
of alcohol
G56 Mononeuropathies of upper limb
M51 Other intervertebral disc disorders
M62 Other disorders of muscle
M75 Shoulder lesions
Fig. 2 Venn diagrams with the number of shared direct and inverse comorbidities between Down syndrome (DS), Klinefelter syndrome (KS),
and Turner syndrome (TS) patients, respectively. a A total of 17 direct comorbidities were shared between DS, KS, and TS. b No inverse comorbidities
were shared between DS, KS, and TS, but six inverse comorbidities were shared between DS and TS. The shared comorbidities are listed by International
Classification of Diseases version 10 (ICD-10) code and named in the boxes to the right.
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Fig. 3 Comorbidity distributions and life expectancy of Down syndrome (DS), Klinefelter syndrome (KS), and Turner syndrome (TS) patients. a
The age at first diagnosis (x-axis) versus percentage of patients diagnosed (y-axis) for DS, KS, and TS. DS patients are usually diagnosed in early life, TS
patients are usually diagnosed during childhood, and KS patients are usually diagnosed at the age of trying to conceive, with the peak around age 30. See
Fig. 1 for color scheme. b The relative comorbidity burden over the past 20 years for DS, KS, and TS. Again, the colors correspond to the International
Classification of Diseases version 10 (ICD-10) chapters (see Fig. 1). The names of the comorbidities displayed are as follows: E29= Testicular dysfunction;
F79= Unspecified mental retardation; G40= Epilepsy; H26=Other cataract; H50=Other strabismus; H52= Disorders of refraction and accommodation;
H65= Nonsuppurative otitis media; H66= Suppurative and unspecified otitis media; H90= Conductive and sensorineural hearing loss; H91=Other
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year for DS, KS, and TS. The life expectancy for DS and TS has increased over the past 20 years whereas the life expectancy for KS has not changed. The
median age of the patients in the registry has slightly decreased for DS, but increased for KS and TS.
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mosaic and mosaic patients (Fig. S3d). For both DS and TS,
the number of non-mosaic patients highly exceeded the
number of mosaic patients (Table 1). To check whether this
skewed patient numbers and influenced the number of
identified comorbidities, we subdivided the non-mosaic
patients into groups of similar size to the mosaic patients
available and identified comorbidities for these groups
(Table S10). It was apparent from these analyses that the
number of patients affects the number of identified
comorbidities. Still, non-mosaic patients had a much more
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Fig. 4 Comorbidities per International Classification of Diseases version 10 (ICD-10) chapter for the four subgroup comparisons: female and
male Down syndrome (DS) and fragile X syndrome (FXS) and non-mosaic and mosaic DS and Turner syndrome (TS). Significant comorbidities
were extracted from each subgroup and summarized by disease chapter. Each dot represents a comorbidity (orange for females, blue for males, gray for
non-mosaic, and black for mosaic) with a certain relative risk (RR). a Female and male DS were both associated with several comorbidities, but female DS had
more comorbidities from chapter III “Diseases from the blood and blood-forming organs and certain disorders involving the immune mechanism,” while
male DS had more diseases from chapter XIV “Diseases of the genitourinary system.” b Only three significant comorbidities were observed for female FXS,
while males were more severely affected, especially with diseases from chapter V “Mental and behavioral disorders” and chapter VI “Diseases of the
nervous system.” (c,d) Both DS and TS non-mosaic patients show a more severe phenotype with 211 and 49 significant comorbidities, respectively,
compared with DS and TS mosaic patients, with only 16 and 1 comorbidities, respectively. Titles of disease chapters are shortened (see Fig. 1). See
Tables S3–S7 for more information.
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severe phenotype than mosaic patients. This was also reflected
by the earlier age at diagnosis for non-mosaic compared with
mosaic patients (Fig. S4).
DISCUSSION
We present a population-wide and comparative analysis on
direct and inverse comorbidities of the 11 most prevalent
chromosome abnormalities in the DNPR that contains
patients of high ancestral homogeneity. This registry contains
6.9 million patients giving strong statistical power to perform
epidemiological studies. Each abnormality showed a unique
comorbidity signature, but clustering of the 14 RR profiles (11
direct and 3 inverse) underlined common risk profiles for
chromosome abnormalities with similar genetic backgrounds.
Most chromosome abnormality patients in the registry
suffered from DS, KS, or TS, and, thus, most comorbidities
were identified for these three. DS, KS, and TS patients all had
an increased RR of “Insulin-dependent diabetes mellitus”
(E10) with TS patients having the highest RR of 4.3. KS and
TS patients also had an increased risk of “Non–insulin-
dependent diabetes mellitus” (E11) and “Unspecified diabetes
mellitus” (E14) (see Table S1 for RRs and p values). This
result was consistent with the fact that type 1 diabetes is more
prevalent in DS patients compared with the general popula-
tion,28 while few cases of type 2 diabetes have been reported.29
However, an increased risk for KS and TS of type 2 diabetes
has previously been reported, compared with very few type 1
diabetes cases.30,31
Our results indicate that DS patients have lower risk of
some solid tumors (lung, breast, and skin), referred to as
inverse cancer comorbidities, which supports previous find-
ings.32 However, this is a controversial topic33 and the
molecular mechanism of the protective effect against solid
tumors is still poorly understood. Extensive epidemiological
studies point out inverse cancer comorbidities in patients
affected by central nervous system (CNS) disorders and
several other diseases such as DS, Parkinson disease,
schizophrenia, Alzheimer disease, multiple sclerosis, and
Huntington disease.33 It has been reported that DS is among
the CNS disorders most strongly associated with cancer, in
particular acute leukemia, testicular cancer, and gastrointest-
inal tumors.24
The comorbidity burden and life expectancy are inter-
connected. The comorbidity burden can increase due to
patients living longer and, vice versa, the life expectancy can
go up due to better diagnosis and treatment of certain
comorbidities. All three common aneuploidies showed a
change in the relative comorbidity burden over the past 20
years (Fig. 3b). The change in the relative comorbidity burden
can be explained by two hypotheses: (1) the actual prevalence
of comorbidity burden changes, or (2) the health system is
improving at monitoring, discovering, and preventing the
disease.
We performed comorbidity analyses for four subgroups of
patients: female/male DS and FXS and non-mosaic/mosaic DS
and TS. Female FXS only had three direct comorbidities while
males showed a more severe phenotype characterized by 22
comorbidities. This result can be justified by the presence of
an extra X chromosome without FMR1 expansion for
females.10 Because the FMR1 gene is essential for cognitive
development, it has been shown that FXS patients commonly
experience several mental disorders.34 This evidence is
consistent with our results of enrichment of direct comorbid-
ities in males such as “Mild mental retardation” (F70),
“Moderate mental retardation” (F71), “Unspecified mental
retardation” (F79), and “Pervasive developmental disorders”
(F84). Further, we observed the commonly known, more
severe phenotype of non-mosaic compared with mosaic
patients.
DS patients often show an overexpression of amyloid
precursor protein (APP), which is located on chromosome 21.
APP generates β-amyloid, which is the primary component of
the amyloid plaques found in DS and Alzheimer disease (AD)
brains.35 It has been shown that DS patients by the age of 40
have neuropathological changes that are consistent with
AD,36 thus DS patients tend to develop dementia 10–20 years
earlier than the general population.35 This was also evident
from our analysis where non-mosaic patients have a RR of
31.39 of developing AD and the median age of onset was 53
years (Table S6). AD was not a comorbidity of mosaic
DS patients.
Most of the patients in DNPR were diagnosed with the
unspecified diagnosis, thus the subtype of the chromosome
abnormality (non-mosaic/mosaic) was not specified. Our
results underline the importance of taking the genotype into
consideration upon consultation of chromosome abnormality
patients. Even though chromosome abnormalities cannot
currently be cured, medical guidance and treatment can make
it easier to handle these syndromes and relieve some of the
symptoms and comorbidities. Knowledge of the genotype and
the comorbidity risk profile is important to help guide
clinicians when diagnosing, subgrouping, and treating these
patients. Furthermore, the differences and similarities in
comorbidity profiles of chromosome abnormality patients
might assist in uncovering disease mechanisms to understand
the different comorbidity profiles.
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